Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Oct;40(10):2345–2349. doi: 10.1128/aac.40.10.2345

Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component.

S R Hawley 1, P G Bray 1, P M O'Neill 1, D J Naisbitt 1, B K Park 1, S A Ward 1
PMCID: PMC163532  PMID: 8891142

Abstract

Aminoquinoline resistance correlates with lipid solubility at pH 7.2. Consequently, the in vivo dealkylation of amodiaquine, to the less lipid-soluble desethylamodiaquine, is a likely contributor to therapeutic failure in vivo. Therefore, 4-aminoquinoline drugs with lipid solubilities similar to that of amodiaquine, but which are not subject to side chain modification in vivo, should be superior antimalarial agents. In this study, we have identified amopyroquine and N-tertbutylamodiaquine as two such compounds. The values for the logarithms of the partition coefficients for amopyroquine and N-tertbutylamodiaquine are between those for amodiaquine and its dealkylated metabolite, desethylamodiaquine. Both amopyroquine and N-tertbutylamodiaquine possess levels of antimalarial activity greater than that of desethylamodiaquine and significantly reduced cross-resistance patterns; i.e., the former two compounds are not subject to the verapamil-sensitive resistance mechanism. Simple in vitro markers of direct toxicity and potential reactive metabolite formation suggest that these two compounds are no more toxic than amodiaquine and desethylamodiaquine.

Full Text

The Full Text of this article is available as a PDF (210.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Basco L. K., Le Bras J. In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg. 1993 Jan;48(1):120–125. doi: 10.4269/ajtmh.1993.48.120. [DOI] [PubMed] [Google Scholar]
  2. Bitonti A. J., Sjoerdsma A., McCann P. P., Kyle D. E., Oduola A. M., Rossan R. N., Milhous W. K., Davidson D. E., Jr Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science. 1988 Dec 2;242(4883):1301–1303. doi: 10.1126/science.3057629. [DOI] [PubMed] [Google Scholar]
  3. Bray P. G., Boulter M. K., Ritchie G. Y., Howells R. E., Ward S. A. Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1994 Jan;63(1):87–94. doi: 10.1016/0166-6851(94)90011-6. [DOI] [PubMed] [Google Scholar]
  4. Childs G. E., Boudreau E. F., Milhous W. K., Wimonwattratee T., Pooyindee N., Pang L., Davidson D. E., Jr A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg. 1989 Jan;40(1):7–11. doi: 10.4269/ajtmh.1989.40.7. [DOI] [PubMed] [Google Scholar]
  5. Christie G., Breckenridge A. M., Park B. K. Drug-protein conjugates--XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem Pharmacol. 1989 May 1;38(9):1451–1458. doi: 10.1016/0006-2952(89)90184-6. [DOI] [PubMed] [Google Scholar]
  6. Churchill F. C., Patchen L. C., Campbell C. C., Schwartz I. K., Nguyen-Dinh P., Dickinson C. M. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci. 1985 Jan 7;36(1):53–62. doi: 10.1016/0024-3205(85)90285-1. [DOI] [PubMed] [Google Scholar]
  7. Clarke J. B., Maggs J. L., Kitteringham N. R., Park B. K. Immunogenicity of amodiaquine in the rat. Int Arch Allergy Appl Immunol. 1990;91(4):335–342. doi: 10.1159/000235138. [DOI] [PubMed] [Google Scholar]
  8. Cotgreave I. A., Moldéus P. Methodologies for the application of monobromobimane to the simultaneous analysis of soluble and protein thiol components of biological systems. J Biochem Biophys Methods. 1986 Nov;13(4-5):231–249. doi: 10.1016/0165-022x(86)90102-8. [DOI] [PubMed] [Google Scholar]
  9. Desjardins R. E., Canfield C. J., Haynes J. D., Chulay J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979 Dec;16(6):710–718. doi: 10.1128/aac.16.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ekweozor C., Aderounmu A. F., Sodeinde O. Comparison of the relative in vitro activity of chloroquine and amodiaquine against chloroquine-sensitive strains of P. falciparum. Ann Trop Med Parasitol. 1987 Apr;81(2):95–99. doi: 10.1080/00034983.1987.11812100. [DOI] [PubMed] [Google Scholar]
  11. Fitch C. D., Yunis N. G., Chevli R., Gonzalez Y. High-affinity accumulation of chloroquine by mouse erythrocytes infected with Plasmodium berghei. J Clin Invest. 1974 Jul;54(1):24–33. doi: 10.1172/JCI107747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985 Jul;45(7):3002–3007. [PubMed] [Google Scholar]
  13. Geary T. G., Divo A. A., Jensen J. B. Activity of quinoline-containing antimalarials against chloroquine-sensitive and -resistant strains of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 1987;81(3):499–503. doi: 10.1016/0035-9203(87)90175-1. [DOI] [PubMed] [Google Scholar]
  14. Geary T. G., Divo A. D., Jensen J. B., Zangwill M., Ginsburg H. Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro. Implications for mechanism of action of and resistance to the drug. Biochem Pharmacol. 1990 Aug 15;40(4):685–691. doi: 10.1016/0006-2952(90)90302-2. [DOI] [PubMed] [Google Scholar]
  15. Geary T. G., Jensen J. B. Lack of cross-resistance to 4-aminoquinolines in chloroquine-resistant Plasmodium falciparum in vitro. J Parasitol. 1983 Feb;69(1):97–105. [PubMed] [Google Scholar]
  16. Harrison A. C., Kitteringham N. R., Clarke J. B., Park B. K. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol. 1992 Apr 1;43(7):1421–1430. doi: 10.1016/0006-2952(92)90198-r. [DOI] [PubMed] [Google Scholar]
  17. Jensen J. B., Trager W. Plasmodium falciparum in culture: use of outdated erthrocytes and description of the candle jar method. J Parasitol. 1977 Oct;63(5):883–886. [PubMed] [Google Scholar]
  18. Krogstad D. J., Gluzman I. Y., Kyle D. E., Oduola A. M., Martin S. K., Milhous W. K., Schlesinger P. H. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science. 1987 Nov 27;238(4831):1283–1285. doi: 10.1126/science.3317830. [DOI] [PubMed] [Google Scholar]
  19. Lambros C., Vanderberg J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979 Jun;65(3):418–420. [PubMed] [Google Scholar]
  20. Martin S. K., Oduola A. M., Milhous W. K. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science. 1987 Feb 20;235(4791):899–901. doi: 10.1126/science.3544220. [DOI] [PubMed] [Google Scholar]
  21. O'Neill P. M., Harrison A. C., Storr R. C., Hawley S. R., Ward S. A., Park B. K. The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. J Med Chem. 1994 Apr 29;37(9):1362–1370. doi: 10.1021/jm00035a017. [DOI] [PubMed] [Google Scholar]
  22. Peters W., Ekong R., Robinson B. L., Warhurst D. C., Pan X. Q. Antihistaminic drugs that reverse chloroquine resistance in Plasmodium falciparum. Lancet. 1989 Aug 5;2(8658):334–335. doi: 10.1016/s0140-6736(89)90522-9. [DOI] [PubMed] [Google Scholar]
  23. Pinichpongse S., Doberstyn E. B., Cullen J. R., Yisunsri L., Thongsombun Y., Thimasarn K. An evaluation of five regimens for the outpatient therapy of falciparum malaria in Thailand 1980-81. Bull World Health Organ. 1982;60(6):907–912. [PMC free article] [PubMed] [Google Scholar]
  24. Pussard E., Chassard D., Clavier F., Bry P., Verdier F. Pharmacokinetics and metabolism of amopyroquin after administration of two doses of 6 mg/kg im 24 h apart to healthy volunteers. J Antimicrob Chemother. 1994 Nov;34(5):803–808. doi: 10.1093/jac/34.5.803. [DOI] [PubMed] [Google Scholar]
  25. Rogan A. M., Hamilton T. C., Young R. C., Klecker R. W., Jr, Ozols R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 1984 Jun 1;224(4652):994–996. doi: 10.1126/science.6372095. [DOI] [PubMed] [Google Scholar]
  26. Schmidt L. H., Vaughan D., Mueller D., Crosby R., Hamilton R. Activities of various 4-aminoquinolines against infections with chloroquine-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother. 1977 May;11(5):826–843. doi: 10.1128/aac.11.5.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Scott H. V., Tan W. L., Barlin G. B. Antimalarial activity of Mannich bases derived from 4-(7'-bromo-1',5'-naphthyridin-4'-ylamino)phenol and 4-(7'-trifluoromethylquinolin-4'-ylamino)phenol against Plasmodium falciparum in vitro. Ann Trop Med Parasitol. 1987 Apr;81(2):85–93. doi: 10.1080/00034983.1987.11812099. [DOI] [PubMed] [Google Scholar]
  28. Slater L. M., Murray S. L., Wetzel M. W., Wisdom R. M., DuVall E. M. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest. 1982 Nov;70(5):1131–1134. doi: 10.1172/JCI110702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Spielberg S. P. Acetaminophen toxicity in human lymphocytes in vitro. J Pharmacol Exp Ther. 1980 May;213(2):395–398. [PubMed] [Google Scholar]
  30. Thompson D., Constantin-Teodosiu D., Norbeck K., Svensson B., Moldéus P. Metabolic activation of eugenol by myeloperoxidase and polymorphonuclear leukocytes. Chem Res Toxicol. 1989 May-Jun;2(3):186–192. doi: 10.1021/tx00009a011. [DOI] [PubMed] [Google Scholar]
  31. Tingle M. D., Jewell H., Maggs J. L., O'Neill P. M., Park B. K. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol. 1995 Sep 28;50(7):1113–1119. doi: 10.1016/0006-2952(95)00236-s. [DOI] [PubMed] [Google Scholar]
  32. Verdier F., Le Bras J., Clavier F., Hatin I., Blayo M. C. Chloroquine uptake by Plasmodium falciparum-infected human erythrocytes during in vitro culture and its relationship to chloroquine resistance. Antimicrob Agents Chemother. 1985 Apr;27(4):561–564. doi: 10.1128/aac.27.4.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Verdier F., Pussard E., Clavier F., Le Bras J., Gaudebout C. Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria. Antimicrob Agents Chemother. 1989 Mar;33(3):316–321. doi: 10.1128/aac.33.3.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wernsdorfer W. H., Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther. 1991;50(1):95–121. doi: 10.1016/0163-7258(91)90074-v. [DOI] [PubMed] [Google Scholar]
  35. Zamora J. M., Pearce H. L., Beck W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 1988 Apr;33(4):454–462. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES